(Press-News.org) SAN DIEGO – Giving patients better access to primary health care could save nearly $4 billion a year in unnecessary emergency room visits for a single common complaint – urinary tract infections – according to a study by the Vattikuti Urology Institute at Henry Ford Hospital in Detroit.
The study set out to determine the economic burden of 10.8 million patients, with a primary diagnosis of urinary tract infection, who went to U.S. emergency rooms for treatment from the beginning of 2006 to the end of 2009.
The findings will be presented May 6 at the annual meeting of the American Urological Association in San Diego.
"The cost of treating urinary tract infections in an outpatient clinic has already been estimated at under $200 per episode, including the office visit and lab fees," says Jesse D. Sammon, D.O., a researcher at Henry Ford's Vattikuti Urology Institute and lead author of the study. "In this study, we set out to compare that to the cost of treating this common disorder in hospital emergency departments.
"While most people would expect the cost to be higher in an emergency room, we found that it is much higher – more than 10 times the entire cost of treatment in an outpatient clinic."
The Henry Ford research team drew its study population from the Nationwide Emergency Department Sample, the largest all-payer database in the U.S., including statistics representing 20 percent of hospital-based emergency departments.
Of the 10,799,345 patients who were seen for urinary tract infections in emergency departments during the four-year study period, the vast majority – 9 million or 83.3 percent, between 2 million to 2.3 million per year – were treated and released, the researchers found.
Compared to those who were admitted for hospital treatment, this group was:
Younger, with a median age of 32 versus 72.
More likely female, 86.9 percent versus 73.1 percent.
On Medicaid, 24.4 percent versus 13 percent; or private insurance, 32.6 percent versus 17.6 percent.
And more likely to be at the lowest income level, 33.5 percent versus 28.7 percent.
The mean charge for these patients who were treated and released from emergency departments was approximately $2,000 per visit, $1,800 higher than the average cost of treatment in an outpatient clinic, the study found.
"Given these findings, it was not difficult to conclude that improved guidelines for emergency treatment of such a common complaint, and a health care system that offers these patients greater access to primary care physicians could result in a savings of nearly $4 billion a year."
INFORMATION:
END
1. Ambrisentan Not Appropriate for Patients with Idiopathic Pulmonary Fibrosis
Ambrisentan should not be used to treat patients for idiopathic pulmonary fibrosis (IPF). IPF is a fatal form of chronic, progressive lung disease characterized by irreversible scarring around both lungs. IPF causes about 5,000 deaths each year and currently there is no approved treatment. Researchers do not know what causes IPF, but a protein called endothelin-1 that causes the blood vessels to contract and induces lung scarring and proliferation has been associated with the disease. Researchers ...
MINNEAPOLIS – Contrary to a widely accepted belief, African-Americans may have a higher rather than lower risk of developing multiple sclerosis (MS) than Caucasians, according to a new study in the May 7, 2013, print issue of Neurology®, the medical journal of the American Academy of Neurology.
"Our population-based study is the first of its kind to look at this question. The belief (that African- Americans have a lower risk of developing MS) was based on evidence that was problematic," said study author Annette Langer-Gould, MD, with Kaiser Permanente Southern California ...
Minneapolis, MN, May 6, 2013 – Adults with end-stage respiratory failure and pulmonary hypertension requiring ECMO (extracorporeal membrane oxygenation) have been "bridged" toward lung transplantation with novel lung assist devices such as the Novalung. This and related devices work based on pumpless application of oxygenators. A presentation by David M. Hoganson, MD, and colleagues from Washington University School of Medicine in St. Louis at the Congenital Heart Disease Session of the 93rd AATS Annual Meeting describes the first time application of this technology to ...
PASADENA, Calif., May 6, 2013 – Multiple sclerosis is more common in black women than in white women, according to a Kaiser Permanente study published today in the journal Neurology. The findings run contrary to the widely accepted belief that blacks are less susceptible to MS, according to the researchers.
Researchers examined the electronic health records of more than 3.5 million members of Kaiser Permanente Southern California between January 2008 and December 2011 and identified 496 people newly diagnosed with MS. Of these diagnosed cases, black patients had a 47 ...
Boston, Mass. –A quality improvement platform developed at Boston Children's Hospital could help health care provider groups continuously improve their medical practice, curbing costs and improving patient outcomes. Successful outcomes associated with the platform, called Standardized Clinical Assessment and Management Plans (SCAMPs) and supported by a consortium of Massachusetts payers, are featured in the May issue of Health Affairs.
SCAMPs start with existing practice recommendations, but are continuously revised as clinicians learn from everyday patient encounters. ...
Research from King's College London reveals the detailed mechanism behind how stress hormones reduce the number of new brain cells - a process considered to be linked to depression. The researchers identified a key protein responsible for the long-term detrimental effect of stress on cells, and importantly, successfully used a drug compound to block this effect, offering a potential new avenue for drug discovery.
The study, published in Proceedings of the National Academy of Sciences (PNAS) was co-funded by the National Institute for Health Research Biomedical Research ...
Around 150 million people globally are chronically infected with the hepatitis C virus (HCV) – a major cause of liver disease and the fastest growing cause of liver transplantation and liver cancer. 1 New prevention strategies are urgently required as people are continuing to be infected with HCV. Findings, published in Hepatology, reveal the impact of a new antiviral treatment that could potentially reduce HCV rates in some cities affected by chronic HCV prevalence by half over 15 years.
In Europe, the US and other developed countries the majority of HCV infections ...
Some of the earliest results from The Environmental Determinants of Diabetes in The Young (TEDDY) study - a major Europe-USA consortium exploring the causes of type 1 diabetes in children – has found no evidence for viral infection as a cause of the rapid-onset form of the condition. The research appears in Diabetologia, the journal of the European Association for the Study of Diabetes (EASD) and is by Professor Anette-Gabriele Ziegler of the German Research Centre for Environmental Health (Helmholtz Zentrum München), Munich, Germany, and colleagues across the USA and Europe, ...
VIDEO:
Cally Harper of Brown University explains how the bats she studied have evolved to lap up extra nectar using blood-filled "hairs " on their tongues. She also discusses how they could...
Click here for more information.
PROVIDENCE, R.I. [Brown University] — Nectar-feeding bats and busy janitors have at least two things in common: They want to wipe up as much liquid as they can as fast as they can, and they have specific equipment for the job. A study in the ...
NEW YORK, NY (May 6, 2013) – A team of New York Stem Cell Foundation (NYSCF) Research Institute scientists report today the generation of patient-specific bone substitutes from skin cells for repair of large bone defects. The study, led by Darja Marolt, PhD, a NYSCF-Helmsley Investigator and Giuseppe Maria de Peppo, PhD, a NYSCF Research Fellow, and published in the Proceedings of the National Academy of Sciences of the USA, represents a major advance in personalized reconstructive treatments for patients with bone defects resulting from disease or trauma.
This advance ...
